The rapid responses received following the publication of the DAFNE trial reflect the controversy surrounding the current inadequate management of Type 1 diabetes.  While it is true that the approach is not novel (Ullman, 5th Oct; Black,6th Oct; Reed, 9th Oct; Chaufan, 12th October, Cohen, 22nd Oct), it is new to the UK. The biomedical benefits of this intensified approach had been known for some time in parts of Europe [2,3] but is was unclear whether these could be transferred to a British health care setting. furthermore, the impact on quality of life was unknown, as psychological outcomes were not measured in the early German work.
|Journal||British Medical Journal|
|Publication status||Published - 29 Oct 2002|
- Type 1 diabetes
- Health care
- Quality of life